

KWALITY PHARMACEUTICALS LIMITED

Regd. Office:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR –

CIN :- L24232PB1983PLC005426; Phone no. :- 8558820862

Email Id:- ramesh@kwalitypharma.com; Website :- www.kwalitypharma.com

Unaudited Standalone Statement of Financial Results for the Quarter and Nine Months Ended December 31, 2023

(Rs. in lakhs)

Sr.No.	PARTICULARS	Quarter ended			Nine months period ended		Year ended
		December 31, 2023 (Unaudited)	September 30, 2023 (Unaudited)	December 31, 2022 (Unaudited)	December 31, 2023 (Unaudited)	December 31, 2022 (Unaudited)	March 31, 2023 (Audited)
I.	Revenue from operations	7809.50	6964.95	5600.97	21519.45	18219.11	25099.47
II.	Other income	61.77	23.36	35.18	124.75	148.09	294.12
III.	Total Revenue(I+II)	7871.27	6988.30	5636.15	21644.20	18367.21	25393.60
IV.	Expenses						
	(a) Cost of materials consumed	3954.02	3305.91	2388.92	10608.24	8264.77	11322.40
	(b) Purchases of stock-in-trade	62.64	12.50	0.00	85.34	02.66	4.25
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-21.73	96.49	-330.18	21.72	-728.02	-319.94
	(d) Employee benefits expense	800.43	791.64	803.16	2354.15	2202.56	2989.75
	(e) Finance Cost	273.32	241.14	194.97	733.01	435.22	602.04
	(f) Depreciation and amortisation expense	481.15	487.69	354.42	1446.77	1050.23	1491.88
	(g) Other expenses	1343.90	1231.93	1221.80	3872.53	3600.16	5074.14
	Total expenses(IV)	6893.73	6167.29	4633.09	19121.76	14827.58	21164.53
V.	Profit/(Loss) from operations before Exceptional items and Tax (III-IV)	977.55	821.02	1003.06	2522.44	3539.63	4229.07
VI.	Exceptional items	.00	0.00	0.00	0.00	0.00	1652.94
VII.	Profit / (Loss) before Tax (V-VI)	977.55	821.02	1003.06	2522.44	3539.63	2576.13
VIII.	Tax expense:						
	(1) Current tax	246.03	206.63	252.47	634.85	890.85	648.36
	(2) Deferred tax	-38.78	-19.59	27.88	-61.22	-03.01	13.66
	(3) Income tax relating to earlier years	0.00	8.26	0.00	8.26	-30.67	-32.77
	(4) MAT Credit (Entitlement)/Utilised	0.00	.00	0.00	0.00	0.00	.00
IX.	Profit/(Loss) after Tax (VII-VIII)	770.29	625.71	722.71	1940.55	2682.46	1946.88
X.	Other Comprehensive Income(net of tax)						
	(i) Items that will not be reclassified to profit or loss	-.46	-.10	-04.71	-8.86	-25.91	-32.57
	(ii) Items that will be reclassified to profit or loss	.00	.00	.00	.00	.00	.00
	Total Other Comprehensive Income(net of tax)	-.46	-.10	-4.71	-8.86	-25.91	-32.57


Ramesh Kumar



	Total Other Comprehensive Income for the period (IX+X)(Comprehensive Profit/(Loss) and Other Comprehensive Income for the period						
XI.		769.83	625.61	718.00	1931.69	2656.55	1914.31
XII.	Paid up Equity Share Capital (Face value Rs.10 each)	1037.62	1037.62	1037.62	1037.62	1037.62	1037.62
XIII.	Other Equity(excluding revaluation reserve)	.00	.00	.00	.00	.00	19084.90
XIV.	Earnings per equity share (Non annualised) (In Rs.)						
	(1) Basic	7.42	6.03	06.92	18.62	25.60	18.45
	(2) Diluted	7.42	6.03	06.92	18.62	25.60	18.45

FOR KWALITY PHARMACEUTICALS LIMITED

Date:- 06.02.2024
Place:- Amritsar


RAMESH ARORA
Managing Director
DIN: 00462656



KWALITY PHARMACEUTICALS LIMITED

Regd. Office :- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR – 143601

CIN :- L24232PB1983PLC005426; Phone no. :- 8558820862

Email Id:- ramesh@kwalitypharma.com; Website :- www.kwalitypharma.com

Unaudited Consolidated Statement of Financial Results for the Quarter and Nine Months Ended December 31, 2023

(Rs. in lakhs)


Sr.No.	PARTICULARS	Quarter ended			Nine months ended		Year ended
		31st DECEMBER 2023 (Unaudited)	30th September 2023 (Unaudited)	31st DECEMBER 2022 (Unaudited)	31st December 2023 (Unaudited)	31st December 2022 (Unaudited)	31st March 2023 (Audited)
I.	Revenue from operations	7809.50	6964.95	5620.25	21519.45	18222.64	25103.00
II.	Other income	61.77	23.36	35.18	124.75	148.09	294.12
III.	Total Revenue(I+II)	7871.27	6988.30	5655.43	21644.20	18370.74	25397.13
IV.	Expenses						
	(a) Cost of materials consumed	3954.02	3305.91	2388.92	10608.24	8264.77	11322.40
	(b) Purchases of stock-in-trade	62.64	12.50	.00	85.34	2.66	4.25
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-21.73	96.49	-314.42	21.72	-728.02	-319.94
	(d) Employee benefits expense	800.87	792.45	804.81	2356.38	2207.54	2995.93
	(e) Finance Cost	273.32	241.14	194.97	733.01	435.22	602.04
	(f) Depreciation and amortisation expense	481.95	488.49	355.41	1449.18	1053.20	1495.84
	(g) Other expenses	1345.18	1234.49	1231.07	3878.94	3610.16	5086.42
	Total expenses(IV)	6896.25	6171.46	4660.76	19132.80	14845.53	21186.95
V.	Profit before share of profit of equity accounted investees, exceptional items and tax (III-IV)	975.02	816.85	994.67	2511.40	3525.20	4210.18
VI.	Share of profit/(loss) of equity accounted investees (net of income tax)	.00	.00	.00	.00	.00	.00
VII.	Profit before exceptional items and tax (VI+VII)	975.02	816.85	994.67	2511.40	3525.20	4210.18
VIII.	Exceptional items	.00	.00	.00	.00	.00	1652.94
IX.	Profit / (Loss) before Tax (VII-VIII)	975.02	816.85	994.67	2511.40	3525.20	2557.24
X.	Tax expense:						
	(1) Current tax	246.03	206.63	252.47	634.85	890.85	648.36
	(2) Deferred tax	-38.78	-19.59	27.88	-61.22	-3.01	13.66
	(3) Income tax relating to earlier years	.00	8.26	.00	8.26	-30.67	-32.77
	(4) MAT Credit (Entitlement)/Utilised	.00	.00	.00	.00	.00	.00
XI.	Profit/(Loss) after Tax (VII-VIII)	767.76	621.54	714.32	1929.51	2668.03	1927.99
XII.	Other Comprehensive Income						
	(i) Items that will not be reclassified subsequently to profit or loss						
	a) Remeasurement of defined benefit plans(net Tax)	-46	-10	-4.71	-8.86	-25.91	-32.57
	(ii) Items that will be reclassified subsequently to profit or loss	.00	.00	.00	.00	.00	.00
	Exchange differences in translating financial statements of foreign operations	-50	-1.05	-2.00	-4.06	-8.21	-11.36
	Total Other Comprehensive Income(net of tax)	-96	-1.15	-6.71	-12.92	-34.12	-43.93
	Total comprehensive income for the period(XI+XII)	766.81	620.39	707.61	1916.59	2633.91	1884.06

Ramesh


XIII.	Profit/(loss) attributable to:						
	a) Owners of the Company	769.00	623.58	709.98	1934.92	2675.10	1937.24
	b) Non-controlling interests	-1.24	-2.04	-4.38	-5.41	-7.07	-9.26
XIV.	Other comprehensive income attributable to:						
	a) Owners of the Company	-96	-1.15	-6.71	-12.92	-34.12	-43.93
	b) Non-controlling interests	.00	.00	.00	.00	.00	.00
XV.	Total other comprehensive income attributable to:						
	a) Owners of the Company	768.05	622.43	703.27	1922.00	2640.98	1893.32
	b) Non-controlling interests	-1.24	-2.04	-4.38	-5.41	-7.07	-9.26
XVI.	Paid up Equity Share Capital (Face value Rs.10 each)	1037.62	1037.62	1037.62	1037.62	1037.62	1037.62
XVII.	Reserves i.e. Other equity	.00	.00	.00	.00	.00	18934.03
XVIII.	Earnings per equity share (Non annualised) (In Rs.)						
	(1) Basic	7.39	5.99	6.82	18.47	25.38	18.16
	(2) Diluted	7.39	5.99	6.82	18.47	25.38	18.16

Date:- 06.02.2024
Place:- Amritsar

FOR KWALITY PHARMACEUTICALS LIMITED



RAMESH ARORA
Managing Director
DIN: 00462656



Notes:

- 1) The above financial results are prepared in accordance with the Indian Accounting Standards ("Ind AS"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under section 133 of the Act read with Rules, 2015 and relevant amendment thereafter.
- 2) These results have been reviewed and recommended for adoption by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 06, 2024.
- 3) As required under Regulation 33 of the SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Limited Review Reports on the aforesaid unaudited financial results for the quarter and nine months ended 31st December, 2023, which were also approved by the Audit Committee and Board at their meeting held on Tuesday, 06th February, 2024.
- 4) The consolidated accounts have been prepared as per Accounting Standard (AS) 21 on consolidated financial statements.
- 5) As previously disclosed in the financial report for the half year ending September 30, 2023, a fire occurred at the company's manufacturing plant located in Village Nag Kalan, Majitha Road, Amritsar on October 5, 2023. The company has notified the insurance company about the loss of assets, and while an interim claim has been received, the final assessment of the physical damage caused by the fire is still ongoing. Consequently, no impact from the fire-related losses has been accounted for in the financial statements for the quarter ended December 31, 2023, as well as the nine months ended December 31, 2023.


6) List of Subsidiary as on 31st December, 2023 is as under :

Name of Entity	Relationship	Country of Incorporation	% of ownership
Kwality Pharmaceuticals Africa, Limitada	Subsidiary	Africa	51%


7) Figures of Previous Year/Period have been regrouped /recast wherever necessary, in order to make them comparable.

8) The company is primarily engaged in the business of Pharmaceuticals which is single reportable segment for the quarter and nine months ended 31st December, 2023 in accordance with Ind AS 108 - "Operating Segment" and hence no separate segment reporting is given.

For Kwality Pharmaceuticals Limited



(RAMESH ARORA)
MANAGING DIRECTOR
DIN: 00462656



Place: Amritsar
Date: 06-02-2024